# Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Study · id `cardio:ct-nct01442038` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01442038](<https://clinicaltrials.gov/study/NCT01442038>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01442038

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2651 participants.

## Technical summary

Registry record NCT01442038. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-07-15.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2651 participants (enrolled count; ClinicalTrials.gov record NCT01442038, source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)
- Start date: 2011-10 (registry gives no type) (ClinicalTrials.gov record NCT01442038, source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01442038, source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01442038, source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)
- Results first posted: 2016-07-15 (ClinicalTrials.gov record NCT01442038, source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Canada; Czechia; France; Germany; Israel; Italy; Netherlands; Poland; Russia; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01442038, source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01442038-2016-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
- Acronym: RIVER-PCI
- Condition: Coronary Artery Disease
- Condition: Angina Pectoris
- Intervention (Drug): Ranolazine
- Intervention (Drug): Placebo
- Lead sponsor: Gilead Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Gilead Sciences (`cardio:org-gilead-sciences`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial (`cardio:pubmed-26474810`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial (`cardio:pubmed-26555329`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris (`cardio:pubmed-30771861`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3fdd00734a2f8c78e3c1532aa77b184a7c6d58702a9c914c59717b6406cd437d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
